Pharma PIs know that their careers and paychecks depend on their ability to consistently produce study outcomes that will win FDA approval for the subject drug. Such perverse incentives naturally drive research bias, confirmation bias, data tampering, strategic laziness, and deliberate falsification and cheating. PIs routinely covered up adverse events, violated protocols, falsely reported AZT patients as being placebo patients, and lost control of the test product.
